Tower Research Capital (TRC)’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.39K | Sell |
277
-1,144
| -81% | -$9.02K | ﹤0.01% | 4671 |
|
|
2026
Q1 | $9.68K | Buy |
1,421
+349
| +33% | +$2.61K | ﹤0.01% | 3917 |
|
|
2025
Q4 | $9.03K | Buy |
1,072
+760
| +244% | +$8.4K | ﹤0.01% | 3924 |
|
|
2025
Q3 | $4.04K | Sell |
312
-1,504
| -83% | -$17.7K | ﹤0.01% | 4411 |
|
|
2025
Q2 | $17.7K | Buy |
1,816
+673
| +59% | +$7.1K | ﹤0.01% | 3745 |
|
|
2025
Q1 | $13.8K | Buy |
+1,143
| New | +$16.3K | ﹤0.01% | 3331 |
|
|
2024
Q3 | – | Sell |
-2,215
| Closed | -$42.9K | – | 5685 |
|
|
2024
Q2 | $42.9K | Buy |
2,215
+2,031
| +1,104% | +$54.4K | ﹤0.01% | 3216 |
|
|
2024
Q1 | $6.92K | Sell |
184
-573
| -76% | -$23.7K | ﹤0.01% | 4294 |
|
|
2023
Q4 | $22.9K | Buy |
757
+75
| +11% | +$1.64K | ﹤0.01% | 3563 |
|
|
2023
Q3 | $14.9K | Sell |
682
-25
| -4% | -$883 | ﹤0.01% | 3646 |
|
|
2023
Q2 | $27.5K | Buy |
707
+525
| +288% | +$46.3K | ﹤0.01% | 3105 |
|
|
2023
Q1 | $17K | Buy |
182
+97
| +114% | +$12.2K | ﹤0.01% | 3606 |
|
|
2022
Q4 | $13K | Sell |
85
-34
| -29% | -$8.48K | ﹤0.01% | 3566 |
|
|
2022
Q3 | $27K | Buy |
119
+29
| +32% | +$7.36K | ﹤0.01% | 3675 |
|
|
2022
Q2 | $21K | Sell |
90
-374
| -81% | -$82.1K | ﹤0.01% | 3718 |
|
|
2022
Q1 | $148K | Buy |
464
+371
| +399% | +$85.3K | ﹤0.01% | 1952 |
|
|
2021
Q4 | $26K | Buy |
93
+21
| +29% | +$3.6K | ﹤0.01% | 3372 |
|
|
2021
Q3 | $9K | Sell |
72
-99
| -58% | -$12.3K | ﹤0.01% | 4401 |
|
|
2021
Q2 | $28K | Buy |
171
+16
| +10% | +$3.26K | ﹤0.01% | 3556 |
|
|
2021
Q1 | $32K | Buy |
155
+108
| +230% | +$24.8K | ﹤0.01% | 3508 |
|
|
2020
Q4 | $11K | Sell |
47
-98
| -68% | -$20.1K | ﹤0.01% | 4240 |
|
|
2020
Q3 | $28K | Buy |
145
+111
| +326% | +$28.1K | ﹤0.01% | 3745 |
|
|
2020
Q2 | $8K | Buy |
+34
| New | +$6.68K | ﹤0.01% | 4089 |
|
|
2020
Q1 | – | Sell |
-20
| Closed | -$3K | – | 2956 |
|
|
2019
Q4 | $3K | Buy |
20
+16
| +400% | +$8.1K | ﹤0.01% | 2866 |
|
|
2019
Q3 | $4K | Buy |
+4
| New | +$4.47K | ﹤0.01% | 3381 |
|
|
2019
Q2 | – | Sell |
-61
| Closed | -$46K | – | 3587 |
|
|
2019
Q1 | $46K | Buy |
61
+49
| +408% | +$44.5K | ﹤0.01% | 1800 |
|
|
2018
Q4 | $12K | Sell |
12
-8
| -40% | -$10.5K | ﹤0.01% | 2301 |
|
|
2018
Q3 | $35K | Buy |
20
+10
| +100% | +$13K | ﹤0.01% | 1976 |
|
|
2018
Q2 | $10K | Sell |
10
-24
| -71% | -$25.8K | ﹤0.01% | 2767 |
|
|
2018
Q1 | $36K | Buy |
+34
| New | +$62.4K | ﹤0.01% | 1860 |
|
Other funds holding ACET
RCM
O
SCM
SSA
Tower Research Capital (TRC)'s ACET Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Adicet Bio (ACET) stake by 81% in Q2 2026, selling an estimated $9.02K and leaving 277 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4671.
Tower Research Capital (TRC) first reported a position in ACET in Q1 2018 and has held it in 30 quarters since. The position peaked at $148K in Q1 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.
- Tower Research Capital (TRC) held 277 shares of Adicet Bio worth $2.39K as of Q2 2026.
- Tower Research Capital (TRC) sold 1,144 Adicet Bio shares in Q2 2026, an estimated $9.02K.
- Adicet Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4671 holding.
- Tower Research Capital (TRC) first reported a position in Adicet Bio in Q1 2018 and has held it in 30 quarters since.
- Tower Research Capital (TRC)'s Adicet Bio position peaked at $148K in Q1 2022.
- 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.